SCHEMBL1479925

SCHEMBL1479925

NC(=O)/C=C/c1ccc2ccccc2c1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.62
PTPN1 P18031 2/20 0.58
CYP1A2 P05177 2/20 0.55
MEN1 O00255 1/20 0.55
NPC1 O15118 1/20 0.55
CYP2C19 P33261 1/20 0.55
RAB9A P51151 1/20 0.55
KMT2A Q03164 1/20 0.55
RELA Q04206 1/20 0.55
CYP1B1 Q16678 2/20 0.54
CYP1A1 P04798 1/20 0.54
CYP2D6 P10635 1/20 0.54
PTGS1 P23219 1/20 0.53
MAOA P21397 1/20 0.52
MAOB P27338 1/20 0.52
APP P05067 1/20 0.50
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1380884 1.00 CYP3A4 (0.62) CYP3A4PTPN1CYP1A2MEN1NPC1
SCHEMBL30209649 1.00 CYP3A4 (0.62) CYP3A4PTPN1CYP1A2MEN1NPC1
SCHEMBL2744149 0.85 CYP3A4 (0.61) CYP3A4PTPN1CYP1A2MEN1NPC1
SCHEMBL2744147 0.85 CYP3A4 (0.61) CYP3A4PTPN1CYP1A2MEN1NPC1
SCHEMBL78426 0.83 RELA (0.62) CYP3A4PTPN1CYP1A2MEN1NPC1
SCHEMBL29462468 0.83 RELA (0.62) CYP3A4PTPN1CYP1A2MEN1NPC1
SCHEMBL6552210 0.83 RELA (0.62) CYP3A4PTPN1CYP1A2MEN1NPC1
SCHEMBL29966677 0.83 RELA (0.62) CYP3A4PTPN1CYP1A2MEN1NPC1
SCHEMBL78427 0.83 RELA (0.62) CYP3A4PTPN1CYP1A2MEN1NPC1
SCHEMBL1033828 0.82 GRIN2D (0.53) CYP3A4PTPN1MEN1KMT2ARELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2011-06-16 US claimed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 US claimed
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 EP claimed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 US claimed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 EP claimed
CN-1867572-A proteasome inhibitors and methods of use thereof CEPHALON INC (US) 2006-11-22 CN claimed
EP-1660507-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2006-05-31 EP claimed
US-20050107307-A1 Proteasome inhibitors and methods of using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-19 US claimed
WO-2005021558-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2005-03-10 WO claimed
EP-1660507-B2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME MILLENNIUM PHARM INC (US) 2017-01-04 EP disclosed
US-9233115-B2 Proteasome inhibitors and methods of using the same MILLENNIUM PHARMACEUTICALS INC. (US) 2016-01-12 US disclosed
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same CEPHALON, INC. (US) 2014-03-27 US disclosed
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 EP disclosed
US-7576206-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-08-18 US disclosed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 EP disclosed
US-20050107307-A1 Proteasome inhibitors and methods of using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME PSMB11, PSMB5, PSMB6 CYP3A4 3988/4885PTPN1 1321/4885CYP1A2 4407/4885
US-20050107307-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 CYP3A4 3988/4885PTPN1 1321/4885CYP1A2 4407/4885
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same PSMB11, PSMB5, PSMB6 CYP3A4 3988/4885PTPN1 1321/4885CYP1A2 4407/4885
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 CYP3A4 3988/4885PTPN1 1321/4885CYP1A2 4407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.